


Московская Городская Онкологическая больница №62  
Патологоанатомическое отделение

## Гармонизация PD-L1 тестирования НМКРЛ

Савёлов Н.А.

2017



Агент	Платформа	Клон	Порог
Ниволумаб	Dako Link 48	28-8	$\geq 1\%$ TC
Пембролизумаб	Dako Link 48	22C3	$\geq 50\%$ TC и $\geq 1\%$ TC
Атезолизумаб*	Ventana	SP142	$\geq 1\%$ TC/IC
Дурвалумаб*	Ventana	SP263	$\geq 25\%$ TC
Авелумаб*	Dako-based	73-10	$\geq 1\%$ TC





\* препараты не зарегистрированы в России

по Kerr KM & Hirsch FR Arch Pathol Lab Med 2016

PD-L1 в НМКРЛ: антитела






- 22C3, 28-8 and SP263 are comparable, SP142 detects less, while 73-10 stains more PD-L1 positive tumor cells
- PD-L1 scoring on digital images and glass slides show comparable reliability
- Scoring of tumor cell PD-L1 expression by pathologists on tissue samples shows strong reliability
- Scoring of immune cell PD-L1 expression remains challenging for pathologists, with poor reliability
- Scoring of PD-L1 expression on cytology samples may have moderate reliability; this requires further confirmation

no Tsao MS et al. IASLC 2017

### Blueprint 2 – 81 образец



Ratcliffe M et al. doi: 10.1158/1078-0432.CCR-16-2375

### PD-L1 в НМКРЛ – 493 образца

